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mathematical model for the control of dengue using vaccines
. Chao1,∗, S. Halstead2, M.E. Halloran1, I. Longini3
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Dengue Vaccine Initiative, Rockville, MD, USA
University of Florida, Gainesville, FL, USA
Background: Before the widespread deployment of a new
engue vaccine, we need to consider how best to use lim-
ted supplies of vaccine, given the complex dengue transmission
ynamics and the immunological interaction among the four
engue serotypes.
Methods: We developed an individual-level simulation model
or dengue transmission in Ratchaburi Province in central Thailand,
he site of the ﬁrst double-blinded, dengue vaccine randomized
ontrol efﬁcacy trial. The model includes human mobility, a sea-
onal vector population, and the co-circulation of four dengue
erotypes in a population that matches the age and household
tructure of Ratchaburi. We used the model to investigate the best
se of vaccine to reduce the number of cases and dengue-related
ospitalizations.
Results: Simulation results indicate that vaccinating children
educesboth thenumberofdenguecasesandhospitalizationsmore
hanvaccinating the samenumberof adults, but local dengue trans-
ission can only be stopped if approximately 50-70% of children
nd adults are vaccinated. We also simulated multi-year catch-up
ampaigns to estimate their effectiveness.
Conclusion: Our model provides a coherent framework that
ntegrates the natural history and epidemiology of dengue in semi-
ural Thailand. The model can be used to plan mass vaccination
ampaigns, and it will be extended to evaluate coordinated mass
accination and vector control.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.985
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accination against viral hepatitis A and B in adults aged over
0 Years – antibody persistence and immune memory
. Chlibek1,∗, J. Smetana1, V. Bostik2, M. Splino1
University of Defence, Hradec Kralove, Czech Republic
University of defence, Hradec Kralove, Czech Republic
Background: Primary vaccination with combined vaccine
gainst viral hepatitis A (VHA) and viral hepatitis B (VHB) induces
igher anti-hepatitis B surface (anti-HBs) antibody responses and
imilar anti-hepatitis A virus (anti-HAV) antibody responses in
dults aged over 40 years in comparison with concomitant mono-
alent vaccines againstVHAandVHB. Theobjectiveswere to assess,fectious Diseases 16S (2012) e158–e316 e301
in a clinical study, persistence of anti-HAV and anti-HBs antibod-
ies in adults aged over 40 years four years after primary VHA/VHB
vaccination and antibody response following a booster dose of the
vaccine.
Methods: Five hundred and ninety-six subjects aged>40 years
were vaccinated with three doses of the combined VHA/VHB vac-
cine at Months 0, 1, 6 (HAB group) or with concomitant VHA and
VHBvaccines atMonths0, 6 and0, 1, 6 (ENG+HAVandHBVX+VAQ,
respectively). Blood samples were collected one month following
primary vaccination (Month 7) and then at one-year intervals for
four years after the booster dose with the same vaccine as used for
the primary vaccination. The anti-HBs and anti-HAV antibody lev-
els were determined prior to the booster dose and at days 14 and
30 after the booster dose.
Results: At Month 7, > 97% of study subjects were seropositive
for anti-HAV antibodies in all groups analyzed. Four years after
primary vaccination, anti-HAV antibody seropositivity persisted
in >93% of study subjects, increasing to >99% after the booster
dose. At Month 7, the highest proportion of study subjects with
anti-HBs antibody levels > 10 mIU/ml was found in the HAB group
(91.7% versus 79.7% in the ENG+HAV group versus 71.0% in the
HBVX+VAQgroup). Four years after vaccination, anti-HBs antibody
levels of 10 mIU/ml persisted in 57.1% of the HAB study subjects
in comparison with 40.1% and 26.6% of the study subjects in the
ENG+HAV and HBVX+VAQ groups, respectively.
Conclusion: In the adults aged over 40 years, an adequate
anti-HAV antibody response persisted for at least four years after
vaccination and was higher and more sustained in those who
received the combined HAB vaccine.
http://dx.doi.org/10.1016/j.ijid.2012.05.986
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Clinical impact and economic evaluation of organized HPV vac-
cination program in Hong Kong
H. Choi ∗, J.T. Wu
The University of Hong Kong, Hong Kong, China
Background: Tomodel the impact of prophylactic HPV vaccines
against persistent HPV 16/18 infections on the age-speciﬁc inci-
dence of cervical cancer and to assess the associated incremental
cost-effectivenessofHPVvaccinationcompared to cytology screen-
ing only.
Methods: We developed a mathematical model to assess the
impact of adding a mass HPV vaccination program under the
current cervical screening program. Our model comprised deter-
ministic population-level dynamic and stochastic individual-level
components for the development of cervical cancer over the life-
timeof individuals.Weperformedcost-effectiveness analysis (CEA)
of organized HPV vaccination for age 12 girls at 45% coverage with
lifelong protection and 95% efﬁcacy against HPV types 16/18 per-
sistent infections in a 50-year time horizon. Sensitivity analyses on
vaccine effectiveness, vaccination coverage and inclusion of catch-
up programs were also performed.
Results: When 12-year girls were annually vaccinated at
45% coverage, the age-speciﬁc cancer incidence started to drop
substantially (40%-60%) after organized vaccination had begun
